Adicon Acquires Crown Bioscience for $204 Million to Create Global Laboratory Services Platform

Adicon Holdings Limited (搜索)搜索该公司, a leading independent clinical laboratory service provider in China and portfolio company of The Carlyle Group (搜索)搜索该词条, has announced a definitive agreement to acquire Crown Bioscience (搜索)搜索该词条 from JSR Life Sciences (搜索)搜索该词条 LLC for a base consideration of $204 million, including earn-out payments. The transaction, expected to close in mid-2026, marks a transformative milestone that will create a global end-to-end laboratory services platform bridging diagnostics, clinical development, and preclinical research.

Strategic Transformation into Global Platform

The acquisition represents Adicon's evolution from a China-based diagnostics platform to an international laboratory services provider. By combining Adicon's nationwide clinical laboratory network in China with Crown Bioscience (搜索)搜索该词条's global preclinical and translational expertise in oncology (搜索)搜索该疾病 and immuno-oncology (搜索)搜索该疾病, the partnership aims to enhance biomarker strategies, improve translational predictivity, and help biopharmaceutical sponsors advance therapies toward clinical development with greater confidence and speed.

Following completion, approximately 23.1% of Adicon's combined revenue will be generated outside China, underscoring its transformation into a truly international platform. The transaction adds a complementary growth engine to Adicon's resilient diagnostics business, combining stable cash flow from independent clinical laboratory operations with Crown Bioscience (搜索)搜索该词条's high-growth and high-margin contract research organization services.

Crown Bioscience's Leading Capabilities

Crown Bioscience (搜索)搜索该词条 brings world-class preclinical capabilities to the partnership, including the world's largest patient-derived xenograft (搜索)搜索该靶点 (PDX) model collection and advanced tumor organoid (搜索)搜索该靶点 platforms that deliver exceptional translatability and patient response predictivity. The company maintains over 1,000 tumor organoid models and expertise spanning in vitro, in vivo, ex vivo, and in silico methods.

The global contract research organization serves more than 1,100 biopharmaceutical and biotechnology companies worldwide, including all of the top 20 global pharmaceutical companies. Crown Bioscience (搜索)搜索该词条 operates multiple facilities across the United States, Europe, and Asia-Pacific regions, meeting the highest industry standards with accreditation by the College of American Pathologists and the International Organization for Standardization.

Leadership Perspectives

"This acquisition represents an important milestone in Adicon's growth journey," said Yang Ling, Chairwoman of Adicon and Head of Asia Healthcare at Carlyle. "With Crown Bioscience (搜索)搜索该词条's world-class CRO capabilities, Adicon is expanding its reach across the global healthcare value chain – from clinical diagnostics to drug discovery and translational research. This transaction reinforces Adicon's vision to become a trusted partner for biopharma innovation and precision diagnostics."

John Gu, CEO of Crown Bioscience (搜索)搜索该词条, emphasized the strategic importance of the transition: "With Adicon's strong support and the backing of Carlyle's global network and resources, we are poised to accelerate innovation in translational oncology (搜索)搜索该疾病 and expand our capabilities across key global markets. From our new Model Development Center in North Carolina to our advanced imaging and biomarker operations in the UK, we are deepening our commitment to providing clients with local access to cutting-edge science."

Transaction Structure and Timeline

The total purchase price of $204 million includes up to $84 million in earn-out payments contingent on performance, subject to customary adjustments for working capital, indebtedness, transaction expenses, and cash. The transaction structure involves a 100% equity acquisition, with Crown Bioscience (搜索)搜索该词条 becoming a wholly owned subsidiary of Adicon upon completion.

The closing is subject to customary conditions, including shareholder approval and regulatory clearances, with an outside date of nine months plus an automatic extension for three months. Until the transaction closes, Crown Bioscience (搜索)搜索该词条 will continue operating as a wholly owned subsidiary of JSR Life Sciences (搜索)搜索该词条, with no anticipated disruptions to ongoing services, projects, or customer relationships.

Operational Continuity and Growth

Crown Bioscience (搜索)搜索该词条 will operate as a standalone entity under Adicon's ownership, maintaining its scientific leadership and global customer relationships while benefiting from Adicon's complementary capabilities and strategic resources. The company's comprehensive portfolio of translational oncology (搜索)搜索该疾病 services, including patient-derived xenograft (搜索)搜索该靶点 models, tumor organoid (搜索)搜索该靶点 platforms, immuno-oncology (搜索)搜索该疾病 assays, and bioinformatics solutions, will transition to Adicon.

Tim Lowery, President and CEO of JSR Life Sciences (搜索)搜索该词条, noted that "Adicon's deep domain expertise and financial backing from The Carlyle Group (搜索)搜索该词条 will empower Crown to scale its groundbreaking oncology (搜索)搜索该疾病 services to new heights." Crown Bioscience (搜索)搜索该词条 remains committed to serving clients through its global network of facilities, including its headquarters in San Diego and recent investments in the United States and Europe.

The acquisition creates an innovation ecosystem that connects early discovery with clinical validation, combining Crown Bioscience (搜索)搜索该词条's global client base with Adicon's strong relationships with hospitals and healthcare institutions across China. This combination is expected to unlock new revenue opportunities and create long-term shareholder value through a balanced and scalable business model.